Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$7.56M-54.02%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Barber
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 147
- Beta
- 1.50
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.93
Financials
Revenue
$7.56M-54.0%Net Income
$-16.50MEBITDA
$-14.47M-946.6%Free Cash Flow
$-7.63M-334.7%EPS (diluted)
$-0.13Shares Outstanding (diluted)
125.55M+527.7%Operating Expenses
$18.42MCash & Debt
$90.35MReturn of Capital
$0.00Revenue by Segment (annual)
$45.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.55M | $-83.78M | $-0.76 |
| 2024 | $57.56M | $-44.14M | $-0.51 |
| 2023 | $50.58M | $-7.87M | $-0.13 |
| 2022 | $47.68M | $-54.41M | $-1.12 |
| 2021 | $50.83M | $-70.54M | $-1.85 |
| 2020 | $45.85M | $-55.78M | $-1.66 |
| 2019 | $52.61M | $-66.25M | $-2.87 |
| 2018 | $67.43M | $-61.38M | $-2.96 |
| 2017 | $66.92M | $-8.94M | $-0.45 |
| 2016 | $51.78M | $-9.60M | $-0.39 |
Valuation
AQSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+150.00%Social Signal Score
Mentions (16)
- Newsglobenewswire.com·4d ago·Neutral
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will participate in the Piper Sandler 38th Annual Healthcare Conference December 1-3, 2026, in New York City.
View source ↗ - Newsmarketbeat.com·6d ago·Neutral
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision Aquestive Therapeutics NASDAQ: AQST is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call Transcript Aquestive Therapeutics, Inc. ( AQST ) Q3 2026 Earnings Call November 4, 2026 8:00 AM EST Company Participants Faith Pomeroy-Ward Daniel Barber - CEO, President & Director Ernie Toth - Senior VP & CFO Sherry Korczynski - Chief Commercial Officer Melina Cioffi - Senior Vice President of Regulatory Affairs Matthew Greenhawt - Chief Medical Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research D…
View source ↗ - Newsmarketbeat.com·18d ago·Negative
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call Aquestive Therapeutics NASDAQ: AQST said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administration approval.
View source ↗ - Newszacks.com·19d ago·Negative
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approval Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report financial results for the third quarter ended September 30, 2026, and provide an update on recent developme…
View source ↗ - Newsseekingalpha.com·37d ago·Neutral
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade Aquestive Therapeutics received FDA acceptance for the Anaphylm NDA resubmission, targeting a March 16, 2027 PDUFA date. Resubmission addresses prior FDA concerns with improved human factors data, showing a significant reduction in packaging and administration errors. I upgrade AQST to Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030, despite competitive and reimbursement risks.
View source ↗ - Newsglobenewswire.com·38d ago·Negative
… Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphy…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
… biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company's Board of Directors, effective October 14, 2026.
View source ↗ - Newsglobenewswire.com·66d ago·Negative
…he applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™ (dibutepinephr…
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Negative
Aquestive Therapeutics Q2 Earnings Call Highlights Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.
View source ↗ - Newszacks.com·103d ago·Negative
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·103d ago·Neutral
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update.
View source ↗ - Newsbenzinga.com·104d ago·Negative
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.11 per share
Typical surprise -27.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.13 vs $-0.12miss
- Tue, Aug 11$-0.18 vs $-0.10miss
- Wed, May 13$-0.07 vs $-0.14beat
- Wed, Mar 4$-0.26 vs $-0.13miss
- Wed, Nov 5$-0.14 vs $-0.11miss
- Mon, Aug 11$-0.14 vs $-0.18beat
Estimates and results for AQST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AQST officers and directors.
- Bought
- $99k
- Sold
- $4.1m
2 trades
25 trades
- Davis Matthew W.sold
- Daly Richard Jbought
- Daly Richard Jbought
- Barber Danielsold
- Barber Danielsold
- Korczynski Sherrysold
- Barber Danielsold
- Barber Danielsold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AQST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
